{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:55:58Z","timestamp":1773212158591,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-128325OB-I00"],"award-info":[{"award-number":["PID2021-128325OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-118127RB-I00"],"award-info":[{"award-number":["PID2020-118127RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n,Spain","doi-asserted-by":"crossref","award":["PDC2022-133085-I00"],"award-info":[{"award-number":["PDC2022-133085-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n,Spain","doi-asserted-by":"crossref","award":["FJC2021-047571-I"],"award-info":[{"award-number":["FJC2021-047571-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI175134"],"award-info":[{"award-number":["R01AI175134"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health,United States","award":["R01AI173171"],"award-info":[{"award-number":["R01AI173171"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1054480"],"award-info":[{"award-number":["OPP1054480"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-85346-y","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:36:03Z","timestamp":1737624963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates"],"prefix":"10.1038","volume":"15","author":[{"given":"In\u00e9s","family":"Bouz\u00f3n-Arn\u00e1iz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel Brice","family":"Feufack-Donfack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malen","family":"Ea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Orban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Popovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Rom\u00e1n-\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino Nicol\u00f2","family":"Fallica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara","family":"Dom\u00ednguez-Asenjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa M.","family":"Arce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mallo-Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Mu\u00f1oz-Torrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus C. S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Fern\u00e0ndez-Busquets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"85346_CR1","volume-title":"World Malaria Report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. World Malaria Report 2023 (Internet Communication, 2023). https:\/\/www.who.int\/publications\/i\/item\/9789240086173"},{"key":"85346_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens, M. B. RTS,S\/AS01 vaccine (MosquirixTM): an overview. Hum. Vaccin. Immunother. 16, 480\u2013489 (2020).","journal-title":"Hum. Vaccin Immunother"},{"key":"85346_CR3","volume-title":"WHO recommends groundbreaking malaria vaccine for children at risk","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk (Internet Communication, 2022)."},{"key":"85346_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40475-018-0133-y","volume":"5","author":"TA Tizifa","year":"2018","unstructured":"Tizifa, T. A. et al. Prevention efforts for malaria. Curr. Trop. Med. Rep. 5, 41\u201350 (2018).","journal-title":"Curr. Trop. Med. Rep."},{"key":"85346_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1473-3099(19)30394-9","volume":"19","author":"D M\u00e9nard","year":"2019","unstructured":"M\u00e9nard, D. & Fidock, D. A. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. Lancet Infect. Dis. 19, 916\u2013917 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"85346_CR6","doi-asserted-by":"crossref","unstructured":"Mathieu, L. C. et al. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. eLife 9, e51015 (2020).","DOI":"10.7554\/eLife.51015"},{"key":"85346_CR7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMc2117480","volume":"386","author":"BH Stokes","year":"2022","unstructured":"Stokes, B. H., Ward, K. E. & Fidock, D. A. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 386, 1385\u20131386 (2022).","journal-title":"N Engl. J. Med."},{"key":"85346_CR8","doi-asserted-by":"crossref","unstructured":"Rosenthal, P. J. et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect. Dis. 24, e591\u2013e600 (2024).","DOI":"10.1016\/S1473-3099(24)00141-5"},{"key":"85346_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s40471-021-00266-5","volume":"8","author":"MM Ippolito","year":"2021","unstructured":"Ippolito, M. M., Moser, K. A., Kabuya, J. B., Cunningham, C. & Juliano, J. J. Antimalarial drug resistance and implications for the WHO Global Technical Strategy. Curr. Epidemiol. Rep. 8, 46\u201362 (2021).","journal-title":"Curr. Epidemiol. Rep."},{"key":"85346_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(02)00239-6","volume":"2","author":"C Wongsrichanalai","year":"2002","unstructured":"Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. & Meshnick, S. R. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2, 209\u2013218 (2002).","journal-title":"Lancet Infect. Dis."},{"key":"85346_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","volume":"74","author":"KJ Wicht","year":"2020","unstructured":"Wicht, K. J., Mok, S. & Fidock, D. A. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annu. Rev. Microbiol. 74, 431\u2013454 (2020).","journal-title":"Annu. Rev. Microbiol."},{"key":"85346_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jgar.2021.09.001","volume":"27","author":"N Noreen","year":"2021","unstructured":"Noreen, N. et al. New insights into the spread of resistance to artemisinin and its analogues. J. Glob. Antimicrob. Resist. 27, 142\u2013149 (2021).","journal-title":"J. Glob Antimicrob. Resist."},{"key":"85346_CR13","doi-asserted-by":"publisher","DOI":"10.30875\/6c551ba0-en","volume-title":"World Malaria Report 2021","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. World Malaria Report 2021 (Internet Communication, 2021). https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2021"},{"key":"85346_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12936-019-2955-z","volume":"18","author":"NJ White","year":"2019","unstructured":"White, N. J. Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malar. J. 18, 338 (2019).","journal-title":"Malar. J."},{"key":"85346_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.pt.2020.03.009","volume":"36","author":"RN Price","year":"2020","unstructured":"Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K. & Mendis, K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 36, 560\u2013570 (2020).","journal-title":"Trends Parasitol."},{"key":"85346_CR16","doi-asserted-by":"crossref","unstructured":"Leishmania: an urgent need for new treatments. EBioMedicine 87, 104440 (2023).","DOI":"10.1016\/j.ebiom.2023.104440"},{"key":"85346_CR17","doi-asserted-by":"publisher","first-page":"1122411","DOI":"10.3389\/fimmu.2023.1122411","volume":"14","author":"U Ornellas-Garcia","year":"2023","unstructured":"Ornellas-Garcia, U., Cuervo, P. & Ribeiro-Gomes, F. L. Malaria and leishmaniasis: updates on co-infection. Front. Immunol. 14, 1122411 (2023).","journal-title":"Front. Immunol."},{"key":"85346_CR18","doi-asserted-by":"publisher","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre, A. et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl. Trop. Dis. 11, e0006052 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"85346_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14728222.2018.1472241","volume":"22","author":"S Sundar","year":"2018","unstructured":"Sundar, S. & Singh, B. Emerging therapeutic targets for treatment of leishmaniasis. Expert Opin. Ther. Targets\u00a022, 467\u2013486 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"85346_CR20","doi-asserted-by":"publisher","first-page":"11765","DOI":"10.1038\/s41598-018-30040-5","volume":"8","author":"A Hefnawy","year":"2018","unstructured":"Hefnawy, A. et al. Importance of secondary screening with clinical isolates for anti-leishmania drug discovery. Sci. Rep. 8, 11765 (2018).","journal-title":"Sci. Rep."},{"key":"85346_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","volume":"16","author":"JN Burrows","year":"2017","unstructured":"Burrows, J. N. et al. New developments in anti-malarial target candidate and product profiles. Malar. J. 16, 26 (2017).","journal-title":"Malar. J."},{"key":"85346_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12915-022-01374-4","volume":"20","author":"I Bouz\u00f3n-Arn\u00e1iz","year":"2022","unstructured":"Bouz\u00f3n-Arn\u00e1iz, I. et al. The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures. BMC Biol. 20, 197 (2022).","journal-title":"BMC Biol."},{"key":"85346_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1021\/acschemneuro.8b00398","volume":"10","author":"A Espargar\u00f3","year":"2019","unstructured":"Espargar\u00f3, A., Pont, C., Gamez, P., Mu\u00f1oz-Torrero, D. & Sabate, R. Amyloid pan-inhibitors: one family of compounds to cope with all conformational diseases. ACS Chem. Neurosci. 10, 1311\u20131317 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"85346_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molcel.2011.05.013","volume":"43","author":"R Halfmann","year":"2011","unstructured":"Halfmann, R. et al. Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins. Mol. Cell\u00a043, 72\u201384 (2011).","journal-title":"Mol. Cell."},{"key":"85346_CR25","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1073\/pnas.042681399","volume":"99","author":"MF Perutz","year":"2002","unstructured":"Perutz, M. F., Finch, J. T., Berriman, J. & Lesk, A. Amyloid fibers are water-filled nanotubes. Proc. Natl. Acad. Sci. U. S. A. 99, 5591\u20135595 (2002).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"85346_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gene.2006.03.023","volume":"378","author":"MA DePristo","year":"2006","unstructured":"DePristo, M. A., Zilversmit, M. M. & Hartl, D. L. On the abundance, amino acid composition, and evolutionary dynamics of low-complexity regions in proteins. Gene 378, 19\u201330 (2006).","journal-title":"Gene"},{"key":"85346_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3","volume":"42","author":"P Romero","year":"2001","unstructured":"Romero, P. et al. Sequence complexity of disordered protein. Proteins 42, 38\u201348 (2001).","journal-title":"Proteins"},{"key":"85346_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3389\/fmicb.2018.01737","volume":"9","author":"I Pallar\u00e8s","year":"2018","unstructured":"Pallar\u00e8s, I. et al. Discovering putative prion-like proteins in Plasmodium falciparum: a computational and experimental analysis. Front. Microbiol. 9, 1737 (2018).","journal-title":"Front. Microbiol."},{"key":"85346_CR29","doi-asserted-by":"publisher","first-page":"e02135","DOI":"10.1128\/AAC.02135-19","volume":"64","author":"A Biosca","year":"2020","unstructured":"Biosca, A. et al. Detection of protein aggregation in live Plasmodium parasites. Antimicrob. Agents Chemother. 64, e02135\u2013e02119 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"85346_CR30","doi-asserted-by":"crossref","unstructured":"Camarero-Hoyos, C. et al. Leveraging the aggregated protein dye YAT2150 for malaria chemotherapy. Pharmaceutics 16, 1290 (2024).","DOI":"10.3390\/pharmaceutics16101290"},{"key":"85346_CR31","doi-asserted-by":"crossref","unstructured":"Kabeche, S., Meister, T. & Yeh, E. A fast-acting inhibitor of blood-stage P. falciparum with mechanism distinct from artemisinin and chloroquine. bioRxiv (2024).","DOI":"10.1101\/2024.08.12.607553"},{"key":"85346_CR32","doi-asserted-by":"publisher","first-page":"e0112723","DOI":"10.1128\/aac.01127-23","volume":"68","author":"L Rom\u00e1n-\u00c1lamo","year":"2024","unstructured":"Rom\u00e1n-\u00c1lamo, L. et al. Effect of the aggregated protein dye YAT2150 on Leishmania parasite viability. Antimicrob. Agents Chemother. 68, e0112723 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"85346_CR33","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1126\/science.351801","volume":"200","author":"P Nguyen-Dinh","year":"1978","unstructured":"Nguyen-Dinh, P. & Trager, W. Chloroquine resistance produced in vitro in an African strain of human malaria. Science 200, 1397\u20131398 (1978).","journal-title":"Science"},{"key":"85346_CR34","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1002\/j.1460-2075.1992.tb05378.x","volume":"11","author":"DA Barnes","year":"1992","unstructured":"Barnes, D. A., Foote, S. J., Galatis, D., Kemp, D. J. & Cowman, A. F. Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J. 11, 3067\u20133075 (1992).","journal-title":"EMBO J."},{"key":"85346_CR35","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1074\/jbc.M608615200","volume":"282","author":"AB Sidhu","year":"2007","unstructured":"Sidhu, A. B. et al. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. 282, 2494\u20132504 (2007).","journal-title":"J. Biol. Chem."},{"key":"85346_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14451","volume":"522","author":"B Baraga\u00f1a","year":"2015","unstructured":"Baraga\u00f1a, B. et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522, 315\u2013320 (2015).","journal-title":"Nature"},{"key":"85346_CR37","doi-asserted-by":"publisher","first-page":"e1007722","DOI":"10.1371\/journal.ppat.1007722","volume":"15","author":"BH Stokes","year":"2019","unstructured":"Stokes, B. H. et al. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. PLoS Pathog. 15, e1007722 (2019).","journal-title":"PLoS Pathog"},{"key":"85346_CR38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1126\/science.1193225","volume":"329","author":"M Rottmann","year":"2010","unstructured":"Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175\u20131180 (2010).","journal-title":"Science"},{"key":"85346_CR39","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41467-023-38774-1","volume":"14","author":"K K\u00fcmpornsin","year":"2023","unstructured":"K\u00fcmpornsin, K. et al. Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum. Nat. Commun. 14, 3059 (2023).","journal-title":"Nat. Commun."},{"key":"85346_CR40","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.1128\/AAC.00857-16","volume":"60","author":"A Siriwardana","year":"2016","unstructured":"Siriwardana, A., Iyengar, K. & Roepe, P. D. Endoperoxide drug cross-resistance patterns for Plasmodium falciparum exhibiting an artemisinin delayed-clearance phenotype. Antimicrob. Agents Chemother. 60, 6952\u20136956 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"85346_CR41","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1073\/pnas.91.3.1143","volume":"91","author":"AF Cowman","year":"1994","unstructured":"Cowman, A. F., Galatis, D. & Thompson, J. K. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. U. S. A. 91, 1143\u20131147 (1994).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"85346_CR42","doi-asserted-by":"publisher","first-page":"e0093722","DOI":"10.1128\/mbio.00937-22","volume":"13","author":"M Carrasquilla","year":"2022","unstructured":"Carrasquilla, M. et al. Barcoding genetically distinct Plasmodium falciparum strains for comparative assessment of fitness and antimalarial drug resistance. mBio 13, e0093722 (2022).","journal-title":"mBio"},{"key":"85346_CR43","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd4683","volume":"14","author":"K Katsuno","year":"2015","unstructured":"Katsuno, K. et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat. Rev. Drug Discov. 14, 751\u2013758 (2015).","journal-title":"Nat. Rev. Drug Discov"},{"key":"85346_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/17460441.2023.2284820","volume":"19","author":"TM Sch\u00e4fer","year":"2024","unstructured":"Sch\u00e4fer, T. M., Pessanha de Carvalho, L., Inoue, J., Kreidenweiss, A. & Held, J. The problem of antimalarial resistance and its implications for drug discovery. Expert Opin. Drug Discov. 19, 209\u2013224 (2024).","journal-title":"Expert Opin. Drug Discov"},{"key":"85346_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.12688\/wellcomeopenres.16168.1","volume":"6","author":"A Ahouidi","year":"2021","unstructured":"Ahouidi, A. et al. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open. Res. 6, 42 (2021).","journal-title":"Wellcome Open. Res."},{"key":"85346_CR46","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/nar\/gkj517","volume":"34","author":"M Llin\u00e1s","year":"2006","unstructured":"Llin\u00e1s, M., Bozdech, Z., Wong, E. D., Adai, A. T. & DeRisi, J. L. Comparative whole genome transcriptome analysis of three Plasmodium falciparum strains. Nucleic Acids Res. 34, 1166\u20131173 (2006).","journal-title":"Nucleic Acids Res."},{"key":"85346_CR47","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1002\/anie.202015845","volume":"60","author":"W Zhan","year":"2021","unstructured":"Zhan, W. et al. Development of a highly selective Plasmodium falciparum proteasome inhibitor with anti-malaria activity in humanized mice. Angew Chem. Int. Ed. Engl. 60, 9279\u20139283 (2021).","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"85346_CR48","doi-asserted-by":"publisher","first-page":"127818","DOI":"10.1016\/j.bmcl.2021.127818","volume":"35","author":"N Everson","year":"2021","unstructured":"Everson, N. et al. Identification of Plasmodium falciparum heat shock 90 inhibitors via molecular docking. Bioorg. Med. Chem. Lett. 35, 127818 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"85346_CR49","unstructured":"Xie, S. C. et al. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proc. Natl. Acad. Sci. U. S. A. 118, e2107213118 (2021)."},{"key":"85346_CR50","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/bfgp\/elz008","volume":"18","author":"AN Cowell","year":"2019","unstructured":"Cowell, A. N. & Winzeler, E. A. The genomic architecture of antimalarial drug resistance. Brief. Funct. Genomics\u00a018, 314\u2013328 (2019).","journal-title":"Brief. Funct. Genomics"},{"key":"85346_CR51","doi-asserted-by":"crossref","unstructured":"Anstey, N. M. et al. The biology and pathogenesis of vivax malaria. Trends Parasitol. 40, 573\u2013590 (2024).","DOI":"10.1016\/j.pt.2024.04.015"},{"key":"85346_CR52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(18)30046-X","volume":"18","author":"TN Nguyen","year":"2018","unstructured":"Nguyen, T. N. et al. The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet Infect. Dis. 18, 565\u2013572 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"85346_CR53","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(23)01249-7","volume":"402","author":"JR Poespoprodjo","year":"2023","unstructured":"Poespoprodjo, J. R., Douglas, N. M., Ansong, D., Kho, S. & Anstey, N. M. Malaria.\u00a0Lancet 402, 2328\u20132345 (2023).","journal-title":"Malar. Lancet"},{"key":"85346_CR54","doi-asserted-by":"publisher","first-page":"e1003799","DOI":"10.1371\/journal.pmed.1003799","volume":"18","author":"KE Battle","year":"2021","unstructured":"Battle, K. E. & Baird, J. K. The global burden of Plasmodium vivax malaria is obscure and insidious. PLoS Med. 18, e1003799 (2021).","journal-title":"PLoS Med."},{"key":"85346_CR55","doi-asserted-by":"publisher","first-page":"e1003890","DOI":"10.1371\/journal.pmed.1003890","volume":"19","author":"AP Phyo","year":"2022","unstructured":"Phyo, A. P., Dahal, P., Mayxay, M. & Ashley, E. A. Clinical impact of vivax malaria: a collection review. PLoS Med. 19, e1003890 (2022).","journal-title":"PLoS Med."},{"key":"85346_CR56","doi-asserted-by":"publisher","first-page":"e1004558","DOI":"10.1371\/journal.ppat.1004558","volume":"11","author":"BE Barber","year":"2015","unstructured":"Barber, B. E. et al. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog. 11, e1004558 (2015).","journal-title":"PLoS Pathog"},{"key":"85346_CR57","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/pharmaceutics15041163","volume":"15","author":"L Rom\u00e1n-\u00c1lamo","year":"2023","unstructured":"Rom\u00e1n-\u00c1lamo, L. et al. In vitro evaluation of aerosol therapy with pentamidine-loaded liposomes coated with chondroitin sulfate or heparin for the treatment of leishmaniasis. Pharmaceutics 15, 1163 (2023).","journal-title":"Pharmaceutics"},{"key":"85346_CR58","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/vetsci7040179","volume":"7","author":"P Mart\u00ednez-Orellana","year":"2020","unstructured":"Mart\u00ednez-Orellana, P., Baxarias, M., Good, L. & Solano-Gallego, L. The effects of polyhexamethylene biguanide (PHMB) and TLR agonists alone or as polyplex nanoparticles against Leishmania infantum promastigotes and amastigotes. Vet. Sci. 7, 179 (2020).","journal-title":"Vet. Sci."},{"key":"85346_CR59","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/jac\/dkz517","volume":"75","author":"S Hendrickx","year":"2020","unstructured":"Hendrickx, S. et al. Transmission potential of paromomycin-resistant Leishmania infantum and Leishmania donovani. J. Antimicrob. Chemother. 75, 951\u2013957 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"85346_CR60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mimet.2005.10.011","volume":"66","author":"S Ganguly","year":"2006","unstructured":"Ganguly, S., Bandyopadhyay, S., Sarkar, A. & Chatterjee, M. Development of a semi-automated colorimetric assay for screening anti-leishmanial agents. J. Microbiol. Methods\u00a066, 79\u201386 (2006).","journal-title":"J. Microbiol. Methods"},{"key":"85346_CR61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.actatropica.2004.06.006","volume":"92","author":"VS Amato","year":"2004","unstructured":"Amato, V. S. et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 92, 127\u2013132 (2004).","journal-title":"Acta Trop."},{"key":"85346_CR62","doi-asserted-by":"publisher","first-page":"11901","DOI":"10.1038\/ncomms11901","volume":"7","author":"VC Corey","year":"2016","unstructured":"Corey, V. C. et al. A broad analysis of resistance development in the malaria parasite. Nat. Commun. 7, 11901 (2016).","journal-title":"Nat. Commun."},{"key":"85346_CR63","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1126\/science.aan4472","volume":"359","author":"AN Cowell","year":"2018","unstructured":"Cowell, A. N. et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science 359, 191\u2013199 (2018).","journal-title":"Science"},{"key":"85346_CR64","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1021\/acsinfecdis.1c00322","volume":"7","author":"B Forte","year":"2021","unstructured":"Forte, B. et al. Prioritization of molecular targets for antimalarial drug discovery. ACS Infect. Dis. 7, 2764\u20132776 (2021).","journal-title":"ACS Infect. Dis."},{"key":"85346_CR65","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.1038\/ncomms14240","volume":"8","author":"ES Istvan","year":"2017","unstructured":"Istvan, E. S. et al. Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commun. 8, 14240 (2017).","journal-title":"Nat. Commun."},{"key":"85346_CR66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.chom.2015.01.014","volume":"17","author":"AR Gomes","year":"2015","unstructured":"Gomes, A. R. et al. A genome-scale vector resource enables high-throughput reverse genetic screening in a malaria parasite. Cell Host Microbe\u00a017, 404\u2013413 (2015).","journal-title":"Cell. Host Microbe"},{"key":"85346_CR67","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85346-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85346-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85346-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:12:46Z","timestamp":1737666766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85346-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85346"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85346-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A patent application (priority number: EP21382949.2; application number: PCT\/EP2022\/079438; application date: 21\/10\/2022) has been filed to protect some of the results presented in the paper, which includes as inventors IB-A, EMA, DM-T and XF-B. All other authors declare they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2941"}}